The state of Arkansas, Arkansas counties, and Arkansas cities have filed a lawsuit against the opioid drug industry in the Circuit Court of Crittenden County. The unique litigation will represent 90 percent of Arkansas's population, with 72 counties and 210 cities participating. "Though other lawsuits have been filed in federal courts across the country, Arkansas is the only state that has united in this fashion," said Chris Villines, executive director of the Association of Arkansas Counties. Don Zimmerman, executive director of the Arkansas Municipal League, commented: "Arkansas's one-voice approach to this lawsuit is one that gives us a seat at the table. Neither the state or any county or city is big enough alone; this litigation approach ensures that recovered damages remain in Arkansas." Arkansas reportedly experiences over 400 fatal overdoses a year, a number that has increased nearly 300 percent since 2000 and "coincides with opioid sales quadrupling". The state ranks second in the nation for ages 12-17 in misuse of opioids (4.67%) behind Alabama, which is the only other state with a higher opioid prescribing rate than Arkansas, according to the U.S. Centers for Disease Control and Prevention. According to PRNewswire, "Arkansas, its counties, cities and taxpayers have funded the enormous societal costs of the opioid epidemic, but have had insufficient revenue to turn the tide of the epidemic". prnewswire.comARCounties.orgARML.org
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Novo Nordisk, The United Laboratories Ink Exclusive License Agreement for Triple Receptor Agonist
March 25th 2025Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.